203 related articles for article (PubMed ID: 37921277)
1. Advances in Cancer Vaccine Research.
Liu N; Xiao X; Zhang Z; Mao C; Wan M; Shen J
ACS Biomater Sci Eng; 2023 Nov; 9(11):5999-6023. PubMed ID: 37921277
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Vaccines for Cancer Immunotherapy.
Wang J; Mamuti M; Wang H
ACS Biomater Sci Eng; 2020 Nov; 6(11):6036-6052. PubMed ID: 33449675
[TBL] [Abstract][Full Text] [Related]
3. Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy.
Lei L; Huang D; Gao H; He B; Cao J; Peppas NA
Sci Adv; 2022 Nov; 8(47):eadc8738. PubMed ID: 36427310
[TBL] [Abstract][Full Text] [Related]
4. In situ photothermal nano-vaccine based on tumor cell membrane-coated black phosphorus-Au for photo-immunotherapy of metastatic breast tumors.
Huang D; Wu T; Lan S; Liu C; Guo Z; Zhang W
Biomaterials; 2022 Oct; 289():121808. PubMed ID: 36137415
[TBL] [Abstract][Full Text] [Related]
5. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
[TBL] [Abstract][Full Text] [Related]
6. Vaccine Strategy in Melanoma.
Kwak M; Leick KM; Melssen MM; Slingluff CL
Surg Oncol Clin N Am; 2019 Jul; 28(3):337-351. PubMed ID: 31079792
[TBL] [Abstract][Full Text] [Related]
7. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
[TBL] [Abstract][Full Text] [Related]
8. Tumor cell-based vaccine: an effective strategy for eradication of cancer cells.
Sadeghi Najafabadi SA; Bolhassani A; Aghasadeghi MR
Immunotherapy; 2022 Jun; 14(8):639-654. PubMed ID: 35481358
[TBL] [Abstract][Full Text] [Related]
9. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
Li WH; Su JY; Li YM
Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
[TBL] [Abstract][Full Text] [Related]
10. Cancer vaccines as promising immuno-therapeutics: platforms and current progress.
Liu J; Fu M; Wang M; Wan D; Wei Y; Wei X
J Hematol Oncol; 2022 Mar; 15(1):28. PubMed ID: 35303904
[TBL] [Abstract][Full Text] [Related]
11. Vaccine-like nanomedicine for cancer immunotherapy.
Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
[TBL] [Abstract][Full Text] [Related]
12. Antigen-specific vaccines for cancer treatment.
Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
[TBL] [Abstract][Full Text] [Related]
13. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK
Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151
[TBL] [Abstract][Full Text] [Related]
14. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
15. Roadmap to next-generation cancer vaccines.
Zheng Y; Zhong Z
J Control Release; 2022 Jul; 347():308-313. PubMed ID: 35561869
[TBL] [Abstract][Full Text] [Related]
16. Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines.
Shi T; Sun M; Lu C; Meng F
Front Immunol; 2023; 14():1125253. PubMed ID: 36895553
[TBL] [Abstract][Full Text] [Related]
17. Current state of vaccine therapies in non-small-cell lung cancer.
Romero P
Clin Lung Cancer; 2008 Feb; 9 Suppl 1():S28-36. PubMed ID: 18540532
[TBL] [Abstract][Full Text] [Related]
18. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
Ni K; Luo T; Nash GT; Lin W
Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
[TBL] [Abstract][Full Text] [Related]
19. Update on active specific immunotherapy with melanoma vaccines.
Conforti AM; Ollila DW; Kelley MC; Gammon G; Morton DL
J Surg Oncol; 1997 Sep; 66(1):55-64. PubMed ID: 9290695
[TBL] [Abstract][Full Text] [Related]
20. Developing recombinant and synthetic vaccines for the treatment of melanoma.
Restifo NP; Rosenberg SA
Curr Opin Oncol; 1999 Jan; 11(1):50-7. PubMed ID: 9914879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
